Title
Category
Credits
Event date
Cost
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
During this activity, multidisciplinary experts discuss the evidence with SGLT-2 inhibitors in reducing cardiorenal risk in patients with and without T2DM, as well as offer additional clinical pearls about their application across specialties.This interactive monograph is organized in an easily digestible format, containing a mix of visuals, audio, video, resources, patient cases, as well as news articles and publications, in order to better facilitate the interpretation of the journey of SGLT-2 inhibitors across trials and to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The 2020 Annual CMHC On Demand - Evolving Paradigms in Cardiometabolic Care: Disparities & Advancements will translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing the whole spectrum of cardiometabolic disorders. The goal is to provide the medical community with evidence-based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated, which increases ASCVD risk, morbidity and mortality in HF patients.In addition, the relatively low insurance approvals for newer LDL-C lowering agents, even for high-risk FH patients, has limited patients’ access to these necessary therapies, increasing their risk for morbidity and mortality. These challenges in diagnosis and treatment are even more apparent in racial and ethnic minorities.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a 15th CMHC Annual meeting session, will cover a concise overview of the efficacy and safety of metabolic surgery in reducing cardiometabolic risk across BMI levels.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes.  As such, current antiplatelet therapy to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes.  However, managing PPG remains one of the most challenging aspects of diabetes care.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The treatment of Atopic Dermatitis (AD) is a clinical challenge. Current treatment regimens are not curative, and patients and caregivers are frequently dissatisfied with and poorly adherent to treatment (O’Toole 2013; Snyder 2015).  The chronic nature of AD demands that clinicians be able to create flexible long-term treatment plans that evolve according to patient need. As more is understood about the disease, it has become apparent that not all forms of AD are epidemiologically and/or clinically equal (Malajian 2015).

Pages